The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.
José Baselga
Consultant or Advisory Role - Roche/Genentech
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Cephalon; Ferrer; Roche
Seock-Ah Im
Consultant or Advisory Role - Roche
Honoraria - Roche
Xavier B. Pivot
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Sanofi
Emma Clark
Employment or Leadership Position - Roche
Stock Ownership - AstraZeneca
Adam Knott
Employment or Leadership Position - Roche
Graham Ross
Employment or Leadership Position - Roche
Stock Ownership - Roche
Sandra M. Swain
Consultant or Advisory Role - Genentech (U); Nektar (U); Novartis (U); Roche (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Sanofi
Other Remuneration - Sanofi